Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Diego, United States and has 28 employees. The company is worth $82.72M. Revenue was $0 in fiscal 2025. It reported a net loss of $57.59M. The share price is 77.2% below its 52-week high of $16.60. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $7.39M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -70.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KZIAKazia Therapeutics Ltd | $7.25 | — | 2.6x | 0.00% | -106.90% | $82.85M |
| PDSBPDS Biotechnology Corp | $1.13 | — | — | 0.00% | -543.97% | $81.9M |
| SERASERA Prognostics Inc | $2.06 | — | 1.4x | 0.00% | -45.03% | $81.27M |
| CTORCitius Oncology Inc | $0.77 |
| — |
| 2.0x |
| 0.00% |
| -126.58% |
| $81.21M |
| LUNGPulmonx Corp | $1.88 | — | 2.1x | 0.00% | -88.87% | $80.74M |
| OKUROnKure Therapeutics, Inc. | $2.10 | — | 0.5x | 0.00% | -46.91% | $85.04M |